
Sign up to save your podcasts
Or


Dr. Felice Rivellese from the Center of Experimental Medicine and Rheumatology at the Queen Mary University in London discusses the results of his presentation at the ACR 2019 with Dr. Caroline Ospelt. In a subanalysis of the pathobiology of the Early Arthitis Cohort (PEAC), Rivellese at al could show that B cell-rich synovitis is associated with disease severity and radiographic progression, in particular, if B cell infiltrates persist after cDMARD treatment.
This randomised, double-blind, placebo-controlled trial by Kroon et al has demonstrated a substantial improvement in painful hand OA with signs of inflammation following six weeks of low-dose prednisolone.
Atul Deodhar, from the Oregon Health & Science University, provides an overview of recent clinical trial results in the area of seronegative Spondylarthritis. He presented the 24-week data of Guselkumab in active psoriatic arthritis patients in the DISCOVER-1 study and compared the phase 3 trials in non-radiographic SpA patients on Ixekizumab (COAST-X) and Secukinumab (PREVENT) with up to 52 week data available.
In this second phase 3 trial, the primary endpoint, BICLA, was achieved, and anifrolumab was superior to placebo for multiple secondary efficacy endpoints, including SRI(4), skin disease, and oral corticosteroid tapering.
In this first phase 3 trial, the primary endpoint, SRI(4), was not achieved, but numeric improvements achieving thresholds associated with clinical benefit were observed for BICLA, oral corticosteroid tapering and other organ-specific endpoints.
Read the full paper on the ARD website: https://ard.bmj.com/content/78/8/1127.
Read the full paper on the ARD website: https://ard.bmj.com/content/78/6/736.
Read the full paper: https://ard.bmj.com/content/78/6/844.
Submit your manuscript here: https://mc.manuscriptcentral.com/ard.
Read the full paper on the Annals of the Rheumatic Diseases website: https://ard.bmj.com/content/77/6/848.
From the publisher's feed

34 Listeners

47 Listeners

6 Listeners

8 Listeners

5 Listeners

3 Listeners

1 Listeners

3 Listeners

9 Listeners

40 Listeners

14 Listeners

1 Listeners

51 Listeners

0 Listeners

6 Listeners

15 Listeners

3 Listeners

27 Listeners

24 Listeners

0 Listeners